Ke Qing-Hua, Zhou Shi-Qiong, Huang Min, Lei Yong, Du Wei, Yang Ji-Yuan
Department of Chemoradiotherapy, Oncology Hospital of Jingzhou, Jingzhou, China.
Asian Pac J Cancer Prev. 2012;13(3):923-6. doi: 10.7314/apjcp.2012.13.3.923.
The aim of this study was to investigate the early outcome of Endostar combined with chemoradiotherapy for advanced cervical cancer. Fifty-two cases (FIGO IIb to IVa) were divided randomly into two groups, receiving chemoradiotherapy alone (CRT group) and Endostar combined with chemoradiotherapy (CRT+E group). For the patients in the CRT+E group, Endostar was administered daily with the dosage of 7.5 mg/m2, and cisplatin was administered weekly with the dosage of 20 mg/m2 during the radiation. The regimens lasted for 4 weeks with no difference in chemoradiotherapy between the two groups. The early outcome complete remission rate was 73.1%, partial remission rate was 23.1% and the total response rate was 96.2% in CRT+E group, a significnat improvement on the 34.6%, 42.3% and 76.9%, respectively, in the CRT group. One year survive rates were 100% and 84.6% in the CRT+E group and CRT groups, the difference being significant. Endostar combined with chemoradiotherapy can improve the early outcome of the advanced cervical cancer, and adverse effects were not encountered.
本研究旨在探讨恩度联合放化疗治疗晚期宫颈癌的近期疗效。52例（国际妇产科联盟（FIGO）IIb至IVa期）患者被随机分为两组，分别接受单纯放化疗（CRT组）和恩度联合放化疗（CRT+E组）。CRT+E组患者在放疗期间每天给予恩度，剂量为7.5mg/m²，每周给予顺铂，剂量为20mg/m²。治疗方案持续4周，两组放化疗方案无差异。CRT+E组近期疗效完全缓解率为73.1%，部分缓解率为23.1%，总有效率为96.2%，分别显著高于CRT组的34.6%、42.3%和76.9%。CRT+E组和CRT组的1年生存率分别为100%和84.6%，差异有统计学意义。恩度联合放化疗可提高晚期宫颈癌的近期疗效，且未出现不良反应。
